MN-ENTRUST-DATACARD
7.6.2019 07:44:06 CEST | Business Wire | Press release
Entrust Datacard , a leading provider of trusted identity and secure issuance technology solutions, completed its previously-announced acquisition of nCipher Security , formerly Thales's market-leading general purpose hardware security module (HSM) business.
The general purpose HSM market is growing quickly, driven by global demand for stronger data and application security, increased encryption, and privacy regulations such as the EU General Data Protection Regulation (GDPR) and the electronic identification, authentication and trust services (eIDAS) regulation. HSMs offer the highest levels of cryptographic security, and are deployed to minimize network and cybersecurity risks from cloud services, Internet of Things (IoT) devices and other digital initiatives.
“We are extremely pleased to complete this acquisition and bring nCipher’s exceptional talent and technology into the Entrust Datacard portfolio. The need for secure network access and data integrity continues to multiply – from mobile devices and cloud services to connected IoT devices and digital payments. The use of HSMs is expanding across all of these domains. With nCipher now part of our solution portfolio, customers will see benefit from our expanded offerings for the most sensitive, high assurance use cases,” said Todd Wilkinson, president and CEO of Entrust Datacard.
General purpose HSMs are a core component of Entrust Datacard's solutions and are an underlying part of the security infrastructure of the company's public key infrastructure (PKI) and secure sockets layer (SSL) offerings. Entrust Datacard will offer the nCipher solution with its on-premise and managed PKI offerings, and its IoT device credentialing, authorization and lifecycle management offerings. By joining Entrust Datacard, nCipher will be able to expand its compliance capabilities from trusted hardware to include trusted identities, and grow its cloud capabilities to offer customers more advanced solutions from Entrust Datacard’s secure hosting facilities.
“nCipher is excited to join the talented Entrust Datacard team. This acquisition quickly expands the global footprint for nCipher solutions and accelerates our strategy for ‘as-a-service’ offerings,” said Cindy Provin, CEO of nCipher Security. “HSMs provide a foundation of trust for business applications such as PKI, blockchain, mobile payments and code signing. As a single company, Entrust Datacard is positioned to effectively secure our customers’ sensitive information and business critical applications as they implement new digital initiatives.”
More than 300 nCipher employees are now part of the Entrust Datacard team. The nCipher Security business will continue to be based in Sunrise, Fla., with a cybersecurity development center in Cambridge, UK and a sales support center in Hong Kong. Additional terms of the acquisition are undisclosed.
For more information about the Entrust Datacard acquisition of nCipher Security, visit: www.entrustdatacard.com/pages/ncipher-acquisition .
About nCipher Security
Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency. It also multiplies the security risks.
nCipher Security, a leader in the general purpose hardware security module (HSM) market, empowers world-leading organizations by delivering trust, integrity and control to their business critical information and applications.
Our cryptographic solutions secure emerging technologies – cloud, IoT, blockchain, digital payments – and help meet new compliance mandates, using the same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business critical applications, ensuring the integrity of your data and putting you in complete control – today, tomorrow, at all times. For more information, visit www.ncipher.com .
About Entrust Datacard Corporation
Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Celebrating 50 years in 2019, Entrust Datacard offers the trusted identity and secure transaction technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates and secure communications. With more than 2,200 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005937/en/
Contact:
Michelle Morgan-Nelsen Entrust Datacard, Public Relations +1 952 988 1796 michelle.morgan-nelsen@entrustdatacard.com
Liz Harris nCipher Security, Corporate Communications +44 7973 903648 Liz.Harris@ncipher.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
